Abstract

Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial
Marina Kremyanskaya ...
Blood | VOL. 138
Marina Kremyanskaya, et. al.Marina Kremyanskaya ...
05 Nov 2021
A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia
John Mascarenhas ... Srdan Verstovsek
Blood | VOL. 138
John Mascarenhas, et. al.John Mascarenhas ... Srdan Verstovsek
05 Nov 2021
Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial
Vikas Gupta ... Moshe Talpaz
Blood | VOL. 138
Vikas Gupta, et. al.Vikas Gupta ... Moshe Talpaz
05 Nov 2021
Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly
Jean-Jacques Kiladjian ... Animesh Pardanani
Blood | VOL. 138
Jean-Jacques Kiladjian, et. al.Jean-Jacques Kiladjian ... Animesh Pardanani
05 Nov 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis.
Ayalew Tefferi ... Tiziano Barbui
Blood | VOL. -
Ayalew Tefferi, et. al.Ayalew Tefferi ... Tiziano Barbui
08 Aug 2024
CDK9 phosphorylates RUNX1 to promote megakaryocytic fate in megakaryocytic-erythroid progenitors.
Nayoung Kwon ... Diane S Krause
Blood | VOL. -
Nayoung Kwon, et. al.Nayoung Kwon ... Diane S Krause
05 Aug 2024
Asciminib Monotherapy as Frontline Treatment of Chronic Phase Chronic Myeloid Leukaemia – Results from the ASCEND Study
David T Yeung ... Timothy P Hughes
Blood | VOL. -
David T Yeung, et. al.David T Yeung ... Timothy P Hughes
05 Aug 2024
Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS.
Esteban Arrieta-Bolaños ... Katharina Fleischhauer
Blood | VOL. -
Esteban Arrieta-Bolaños, et. al.Esteban Arrieta-Bolaños ... Katharina Fleischhauer
05 Aug 2024
View more papers